The global insurtech market is expected to expand from USD 14 billion in 2026 to USD 638 billion by 2035, driven by adoption of AI, cloud computing, blockchain, machine learning, and IoT. Health insurtech leads market share, while North America dominates regionally with Asia expected to achieve higher growth rates. Strategic partnerships between traditional insurers and startups are fueling innovation and scalability.

Clover Health announced that CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The company grew Medicare Advantage membership ~48% year-over-year to over 157,000 members. Clover maintained its #1 ranking among non-SNP PPO plans with a HEDIS score of 4.82 out of 5 Stars for the third consecutive year, demonstrating the effectiveness of its Counterpart Assistant platform in supporting physician decision-making.

Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D. to its Board of Directors, effective immediately. Senator Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. The appointments fill two board vacancies and bring the board to nine directors. Both appointees bring extensive experience in healthcare policy, Medicare Advantage, clinical practice, and business strategy.

Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., to its Board of Directors, effective immediately. Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. Both appointments bring complementary expertise in healthcare policy, Medicare Advantage, clinical practice, and business strategy to strengthen the company's governance and execution.

Clover Health CEO Andrew Toy sold 62,711 shares worth ~$292,860 on July 15, 2026, to cover tax withholding obligations from RSU vesting. The sale is non-discretionary and doesn't reflect a change in conviction. Toy retains a $44.68 million stake (~2% ownership). The stock has gained 57% over the past year but dropped 20% in July following a data breach disclosure. Q2 earnings are expected in early August.

Clover Health CEO Andrew Toy sold 313,476 shares worth $1.67 million on July 1, 2026, representing a 3.16% reduction in his direct holdings. The sale was a non-discretionary tax withholding event tied to RSU vesting, not a signal of lost confidence. Toy retains 9.6 million shares, maintaining significant alignment with shareholders. The sale comes amid strong company performance, including a court-mandated Medicare rating upgrade and 51% year-over-year membership growth in Q1 2026.

Clover Health board member Dr. Carladenise Armbrister Edwards sold 67,160 shares (~$230,000) on May 18, 2026, reducing her direct holdings by 19%. The sale occurred during muted stock performance, but the director has not sold additional shares despite the stock subsequently reaching a 52-week high of $5.49 following a favorable court ruling and strong Q1 earnings with 62% revenue growth.

Conrad Wai, CEO of Clover Health's Counterpart Health subsidiary, sold 220,426 shares for approximately $879,000 on May 28, 2026. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as Wai retains over 2.5 million shares. The transaction occurred during a strong period for the company, with Q1 2026 showing 62% revenue growth and 51% Medicare Advantage membership growth.

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.

The global insurtech market is projected to grow from $14 billion in 2026 to $638 billion by 2035, at a CAGR of 41.45%. Growth is driven by AI, blockchain, cloud computing, and machine learning technologies, with collaborations between traditional insurers and startups accelerating innovation. North America leads the market, while Asia is expected to grow faster. Health insurance, managed services, and cloud computing segments dominate, with healthcare sector showing highest future growth potential.

Fiserv reported disappointing Q3 earnings, with revenue and earnings missing analyst expectations, leading to a 30% stock collapse and a comprehensive strategic restructuring including leadership changes and reduced financial guidance.

Chamath Palihapitiya launched a new SPAC called American Exceptionalism Acquisition Corp, but is advising retail investors to avoid it due to high risk and complex investment structure. He emphasized that 98.7% of the SPAC was allocated to institutional investors.